TaiGen Biopharmaceuticals Holdings (ROCO:4157) LT-Debt-to-Total-Asset : 0.04 (As of Dec. 2024)

View and export this data going back to 2013. Start your Free Trial

What is TaiGen Biopharmaceuticals Holdings LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. TaiGen Biopharmaceuticals Holdings's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.04.

TaiGen Biopharmaceuticals Holdings's long-term debt to total assets ratio declined from Dec. 2023 (0.05) to Dec. 2024 (0.04). It may suggest that TaiGen Biopharmaceuticals Holdings is progressively becoming less dependent on debt to grow their business.

TaiGen Biopharmaceuticals Holdings LT-Debt-to-Total-Asset Historical Data

The historical data trend for TaiGen Biopharmaceuticals Holdings's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TaiGen Biopharmaceuticals Holdings LT-Debt-to-Total-Asset Chart

TaiGen Biopharmaceuticals Holdings Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.03

0.02

0.05

0.04

TaiGen Biopharmaceuticals Holdings Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.05	0.05	0.04	0.04	0.04

TaiGen Biopharmaceuticals Holdings LT-Debt-to-Total-Asset Calculation

TaiGen Biopharmaceuticals Holdings's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	42.386	/	1174.282
	=	0.04

TaiGen Biopharmaceuticals Holdings's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	42.386	/	1174.282
	=	0.04

TaiGen Biopharmaceuticals Holdings (ROCO:4157) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

TaiGen Biopharmaceuticals Holdings LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of TaiGen Biopharmaceuticals Holdings's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

TaiGen Biopharmaceuticals Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TaiGen Biopharmaceuticals Holdings Ltd (ROCO:4157) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 138 Xinming Road, 7th Floor, Neihu District, Taipei, TWN, 114

Website

https://www.taigenbiotech.com/tw

TaiGen Biopharmaceuticals Holdings Ltd is mainly engaged in the research and development of new drugs, including the selection of drug candidates, pre-IND trials and clinical trials. Its operating segment includes development, research and sales of new drugs, and other.

TaiGen Biopharmaceuticals Holdings Headlines

No Headlines